Empros Pharma AB announces today that they have dosed the first patients with anti-obesity drug,
EMP-16 in the third clinical study. The phase 2 trial known as the SESAM study has begun with
dosing patients at each clinic in Uppsala, …

Empros Pharma AB has secured 80.000.000 SEK through private investments. The investment was led by Flerie Invest and will be used to accelerate the development of the obesity drug product EMP16, as well as strengthening the team. 

Arvid Söderhäll, CEO …

Empros Pharma AB has initiated their third clinical trial for their anti-obesity treatment, EMP16. This is a phase 2b trial and follows an earlier successful Proof-of-concept trial.

Ulf Holmbäck, CSO of Empros commented: “This phase 2b study represent a significant …

Stockholm, Sweden 6 February 2023. Empros Pharma AB (“Empros Pharma” or “Empros”) announce
today that they have secured 40.000.000 SEK through private investments. The investment was led
by Flerie Invest and will be used to accelerate the development of …

Our study is now published in the respected journal obesity, and also chosen as “Editor’s Choice” for
the November issue, please find the article here…

Empros will hold its annual general meeting on the 5^th of May. Documents requested by shareholders no later than 26^th of April 2022, will be published here no later than 1 May 2022.…

The pharmacokinetics data from Empros first trial is published. The data demonstrates that EMP16 has a safety comparable to Xenical.

…

On May 25th Empros Pharma started our second clinical trial – a Phase IIa proof-of-concept trial. It is a golden standard randomized, placebo controlled double blinded clinical trial where we compare two different doses of EMP16-02 and placebo. The primary …

Empros first clinical trial, closed in 2017 was recently published in Obesity Science and Practice, see full text article here. In this phase 2a trial Empros compared three different doses of EMP16 with Xenical. The trial demonstrated that EMP16 …

At an extraordinary general meeting held in Q1 2020, Empro’s owners decided to appoint Eugen Steiner, Milan Zdravkovic and Anne Bloch Thomsen as new Directors of the Board. The three new members add competence in entrepreneurship, venture capital logics, Obesity, …

Empros Pharma takes the next important step in the clinical development of the drug candidate EMP16, targeting the growing obesity market. With Vator Securities as Financial Advisor, Empros Pharma has now secured SEK 40m in a fully subscribed share issue …

Det svenska läkemedelsutvecklingsföretaget Empros Pharma AB tar nu nästa steg i den kliniska utvecklingen av läkemedelskandidaten för viktminskning, EMP16. Empros har tillsammans med Vator Securities rest 40 miljoner kronor i en fulltecknad aktieemission för att finansiera en proof-of-concept-studie. Studien som …

CEO Arvid Söderhäll participated in the Bio-Korea conference in Seoul in May. South Korea represents a vibrant region with an impressive traction. Empros Pharma has established contacts with investors, pharmaceutical industry, key opinion leaders, regulatory authority as well as consultants.…

Arvid Söderhäll gives his view on the Obesity market and the perspective of EMP16 in this interview at the Bio Europe conference.…

Swedish Start-Up Pharma reveals positive Phase 2a trial – results from a novel oral medication treatment of obesity

The Swedish Pharmaceutical start-up Empros Pharma AB has new clinical results from a Phase 2a trial of its first novel and unique …

Empros Pharma will be at the  Nordic-American Life science conference in New York, November 13-15.

Meet us there!…

The BIO Europe conference in Berlin 6-8 November.

Meet us there!…